Mar 30, 2020 / 09:00PM GMT
Operator
Good evening, and welcome to Mersana Therapeutics' conference call to review updated XMT-1536 Phase I Dose Escalation Study Data. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Sarah Carmody - Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications
Good evening, and welcome to our call. A short while ago, we issued a press release detailing the updated clinical data from our ongoing Phase I dose escalation study of XMT-1536. This release as well as the slides we will present today are available on the Investors and Media section of our website at www.mersana.com.
A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A. Before I begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of
Mersana Therapeutics, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot